GeneCentric Therapeutics Announces Publication of New Results Showing Clinical Benefit of RNA-based Antifolate Predictive Response Signature (AF-PRS) to Guide Lung Cancer Treatment Selection

GeneCentric Therapeutics, a company specializing in RNA-based diagnostics for precision medicine, has recently published new findings from the Piedmont study. This study utilized real-world data to identify predictive biomarkers for approved first-line treatments in non-small cell lung cancer (NSCLC). The results highlight the clinical benefit of GeneCentric's RNA-based Antifolate Predictive Res..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 21.
  • textsms

"ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023"

The Phase 3 data of donanemab, a potential treatment for Alzheimer's disease, has been announced by the Alzheimer's Association. The data, presented at the Alzheimer's Association International Conference® (AAIC®) 2023 by Eli Lilly and Company, showcases promising advancements in Alzheimer's research and treatment. &nbsp In the TRAILBLAZER-ALZ 2 clinical trial, donanemab demonstrated its ability..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 18.
  • textsms

Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)

Biodexa Ltd, a clinical stage biopharmaceutical company, has successfully completed the enrollment and treatment phase of the Phase 1 study for MTX110. This study focused on treating children with newly diagnosed Diffuse Midline Gliomas (DMGs), a type of primary brain tumor that primarily affects children and has a poor prognosis. The study took place at Columbia University Irving Medical Centre..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 11.
  • textsms

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study

Sorrento Therapeutics, Inc. has announced positive results from a phase IIa study of Abivertinib for the treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) in China. Abivertinib is a novel Bruton's tyrosine kinase (BTK) inhibitor that targets BTK irreversibly. The study included 27 R/R MZL patients treated with Abivertinib, and the overall response rate (ORR) was 59.3%, with 3 pat..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Harbour BioMed, a global biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application (BLA) for batoclimab in the treatment of generalized myasthenia gravis (gMG). This marks the first BLA accepted by NMPA since Harbour BioMed's establishment. Batoclimab is an innovative therapy targeting anti-FcRn treat..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms

Eloxx Pharmaceuticals Highlights Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Positive Phase 2 Results for ELX-02

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, recently held a key opinion leader (KOL) event to discuss the significant unmet medical needs of patients with Alport syndrome. The event featured two renowned experts in Alport syndrome: Professor Detlef Bockenhauer and Professor Rachel Lennon. Alport syndrome is a rare progressive hereditary glomerul..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

Amylyx Pharmaceuticals has received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on its application for conditional marketing authorisation of AMX0035, under the trade name ALBRIOZA, for the treatment of amyotrophic lateral sclerosis (ALS) in adults. Despite this setback, Amylyx remains confident in its CENTAUR trial data and..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 26.
  • textsms

Auxilius Pharma Raises Seed Round of $1 Million and Commences its Clinical Program

Auxilius Pharma has raised $1 million in seed funding to develop its lead asset, AUX-001, a new medication for treating chronic-stable angina pectoris in the US. The company is developing the drug as there have been very few medications developed to address chest pain symptoms suffered by patients with underlying coronary artery disease. Auxilius plans to conduct a first-in-human exploratory pha..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms

IgA의 미생물과의 상호작용 조정

뉴욕시 롱아일랜드에 있는 컬럼비아대학교 의과대학의 연구원들은 IgA가 미생물과의 상호작용을 조정하는 데 중요한 역할을 한다는 것을 발견했습니다. IgA는 면역 체계의 중요한 구성 요소로, 감염을 방지하고 감염이 발생할 경우 염증을 조절하는 역할을 합니다. 이번 연구에서 연구원들은 IgA가 미생물의 부착과 증식을 방지하는 데 도움이 된다는 것을 발견했습니다. 또한 IgA는 미생물이 면역 체계의 다른 부분에 도달하는 것을 방지하는 데 도움이 된다는 것을 발견했습니다. 이 연구 결과는 IgA가 감염 예방과 치료에서 중요한 역할을 한다는 것을 시사합니다.

  • format_list_bulleted 카테고리 없음
  • · 2023. 5. 30.
  • textsms